Sitemap | Contact Us  

Welcome To Taj Pharmaceuticals Ltd API

About Worldwide  |     FAQs    |    Careers     | |        Media Center  |  |    Taj Pharmaceuticals  World   | |     TAJ Group 

       2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved

clopidrogel bisulfate Taj Pharmaceuticals

      India              Latin America/ Caribbean            Africa & Middle East              Asia              Russia              Europe  

Clopidogrel bisulfate Manufacturers in India Suppliers Clopidogrel bisulfate Exporters Distributors Clopidogrel bisulfate api active pharmaceuticals ingredients Clopidogrel bisulfate manufacturers Side Effects bulk drugs raw material Clopidogrel bisulfate companies Side Effects Importers Clopidogrel bisulfate Clopidogrel bisulfate Exporters Clopidogrel bisulfate exporters FDA Clopidogrel bisulfate DMF Symptoms Generic Taj Pharmaceuticals Ltd.

active pharmaceutical ingredients suppliers pharmaceutical Clopidogrel bisulfate manufacturing pharmaceutical drugs pharmaceutical intermediates Clopidogrel bisulfate pharmaceutical chemicals pharmaceutical raw materials Clopidogrel bisulfate active pharmaceutical ingredients Clopidogrel bisulfate committee active pharmaceutical ingredients manufacturer Clopidogrel bisulfate Active Pharmaceutical Ingredients manufacturer Clopidogrel bisulfate exporter drug ingredients pharmaceuticals

Pharmaceuticals API Manufacturer Clopidogrel bisulfate, Clopidogrel bisulfate manufacturer India, Clopidogrel bisulfate product, Clopidogrel bisulfate products, Api preparation, Certificate of Analysis API manufacturer product, Clopidogrel bisulfate anti ulcer product, Certificate of Origin COA Clopidogrel bisulfate COS Clopidogrel bisulfate, pharmaceutical generic, pharmaceutical drug, medical, Clopidogrel bisulfate pharma healthcare, pharma patents, contract MSDS manufacturing Trader Clopidogrel bisulfate pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Clopidogrel bisulfate expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Clopidogrel bisulfate DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Clopidogrel bisulfate ingredients, api, HIV Clopidogrel bisulfate, tablets, capsules, syrup & protein Clopidogrel bisulfate powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Clopidogrel bisulfate gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Clopidogrel bisulfate WHO, UKMHRA Approval

   API >>>
   Pharmaceuticals API List
   Product Development
   Product Search
   Agro Chemicals
   Custom Pharma Services
   Contact Us

clopidrogel bisulfate img


Clopidogrel Bisulfate Clopidogrel Bisulfate

Clopidogrel Bisulfate Clopidogrel Bisulfate






















































HOME >> API >> API List1 >> Clopidogrel Bisulfate

structural formula is as follows: pdf api

(clopidogrel bisulfate) is a thienopyridine class inhibitor of P2Y12 ADP platelet receptors. Chemically it is methyl (+)- (S)-α- (2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5 (4H)-acetate sulfate (1:1). The empirical formula of clopidogrel bisulfate is C16H16ClNO2SH2SO4 and its molecular weight is 419.9.

The structural formula is as follows:

Clopidogrel Bisulfate Formula C16H16ClNO2S,CAS number 135046-48-9

Clopidogrel Bisulfate

Clopidogrel Bisulfate

Clopidogrel bisulfate is a white to off-white powder. It is practically insoluble in water at neutral pH but freely soluble at pH 1. It also dissolves freely in methanol, dissolves sparingly in methylene chloride, and is practically insoluble in ethyl ether. It has a specific optical rotation of about +56.

Plavix for oral administration is provided as either pink, round, biconvex, debossed, film-coated tablets containing 97.875 mg of clopidogrel bisulfate which is the molar equivalent of 75 mg of clopidogrel base or pink, oblong, debossed film-coated tablets containing 391.5 mg of clopidogrel bisulfate which is the molar equivalent of 300 mg of clopidogrel base.

Each tablet contains hydrogenated castor oil, hydroxypropylcellulose, mannitol, microcrystalline cellulose and polyethylene glycol 6000 as inactive ingredients. The pink film coating contains ferric oxide, hypromellose 2910, lactose monohydrate, titanium dioxide and triacetin. The tablets are polished with Carnauba wax.

Acute Coronary Syndrome (ACS)
For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], including patients who are to be managed medically and those who are to be managed with coronary revascularization, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, myocardial infarction (MI), or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia.
For patients with ST-elevation myocardial infarction (STEMI), Plavix has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction, or stroke. The benefit for patients who undergo primary percutaneous coronary intervention is unknown.

The optimal duration of Plavix therapy in ACS is unknown. Recent MI, Recent Stroke, or Established Peripheral Arterial Disease

For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.

Thrombotic thrombocytopenic purpura (TTP)
TTP has been reported rarely following use of clopidogrel bisulfate, sometimes after a short exposure (<2 weeks). TTP is a serious condition that can be fatal and requires urgent treatment including plasmapheresis (plasma exchange). It is characterized by thrombocytopenia, microangiopathic hemolytic anemia (schistocytes [fragmented RBCs] seen on peripheral smear), neurological findings, renal dysfunction, and fever. (See ADVERSE REACTIONS.)


Clopidogrel bisulfate prolongs the bleeding time and therefore should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery, or other pathological conditions (particularly gastrointestinal and intraocular). If a patient is to undergo elective surgery and an antiplatelet effect is not desired, clopidogrel bisulfate should be discontinued 5 days prior to surgery.

Due to the risk of bleeding and undesirable hematological effects, blood cell count determination and/or other appropriate testing should be promptly considered, whenever such suspected clinical symptoms arise during the course of treatment (see ADVERSE REACTIONS).

In patients with recent TIA or stroke who are at high risk for recurrent ischemic events, the combination of aspirin and clopidogrel bisulfate has not been shown to be more effective than clopidogrel bisulfate alone, but the combination has been shown to increase major bleeding.

GI Bleeding
In CAPRIE, clopidogrel bisulfate was associated with a rate of gastrointestinal bleeding of 2%, vs. 2.7% on aspirin. In CURE, the incidence of major gastrointestinal bleeding was 1.3% vs 0.7% (clopidogrel bisulfate + aspirin vs. placebo + aspirin, respectively). Clopidogrel bisulfate should be used with caution in patients who have lesions with a propensity to bleed (such as ulcers). Drugs that might induce such lesions should be used with caution in patients taking clopidogrel bisulfate.

Use in Hepatically Impaired Patients
Experience is limited in patients with severe hepatic disease, who may have bleeding diatheses. Clopidogrel bisulfate should be used with caution in this population.

Use in Renally Impaired Patients
Experience is limited in patients with severe renal impairment. Clopidogrel bisulfate should be used with caution in this population.

Information for Patients
Patients should be told that it may take them longer than usual to stop bleeding, that they may bruise and/or bleed more easily when they take clopidogrel bisulfate or clopidogrel bisulfate combined with aspirin, and that they should report any unusual bleeding to their physician. Patients should inform physicians and dentists that they are taking clopidogrel bisulfate and/or any other product known to affect bleeding before any surgery is scheduled and before any new drug is taken.

Pregnancy Category B. Reproduction studies performed in rats and rabbits at doses up to 500 and 300 mg/kg/day (respectively, 65 and 78 times the recommended daily human dose on a mg/m2 basis), revealed no evidence of impaired fertility or fetotoxicity due to clopidogrel. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of a human response, clopidogrel bisulfate should be used during pregnancy only if clearly needed.

Nursing Mothers
Studies in rats have shown that clopidogrel and/or its metabolites are excreted in the milk. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the nursing woman.

Pediatric Use
Safety and effectiveness in the pediatric population have not been established.

Geriatric Use
Of the total number of subjects in controlled clinical studies, approximately 50% of patients treated with clopidogrel bisulfate were 65 years of age and over. Approximately 16% of patients treated with clopidogrel bisulfate were 75 years of age and over.

The observed difference in risk of thrombotic events with clopidogrel plus aspirin versus placebo plus aspirin by age category is provided in Figure 3 (see CLINICAL STUDIES). The observed difference in risk of bleeding events with clopidogrel plus aspirin versus placebo plus aspirin by age category is provided in Table 3 (see ADVERSE REACTIONS).

Recent MI, Recent Stroke or Established Peripheral Arterial Disease
The recommended daily dose of clopidogrel tablets is 75 mg once daily.

Acute Coronary Syndrome
For patients with acute coronary syndrome (unstable angina/non-Q-wave MI), clopidogrel bisulfate should be initiated with a single 300 mg loading dose and then continued at 75 mg once daily. Aspirin (75 mg-325 mg once daily) should be initiated and continued in combination with clopidogrel bisulfate. In CURE, most patients with Acute Coronary Syndrome also received heparin acutely (see CLINICAL STUDIES).

Clopidogrel tablets can be administered with or without food.

No dosage adjustment is necessary for elderly patients or patients with renal disease (See Clinical Pharmacology: Special Populations.)

Clopidogrel Tablets USP, 75 mg are reddish-brown, round, unscored, film coated tablets, imprinted "APO" on one side and "CL" over "75" on the other side. They are supplied as follows:

Bottles of 30 NDC 60505-0253-1

Bottles of 90 NDC 60505-0253-2

Bottles of 1000 NDC 60505-0253-3

100 Unit Dose NDC 60505-0253-4

Store at 25 C (77 F); excursions permitted to 15 to 30 C (59 to 86 F) [See USP Controlled Room Temperature].

Information Associated with Product:
Detail icon
Product Enquiry Product Quotation Sample Request Place Your Order  
Product Enquiry Product Quotation Sample Request Place Your Order  

Taj Pharmaceuticals API Logo

Clopidogrel Bisulfate

Api Manufacturing At Taj

Acamprosate Calcium

Clomipramine Hcl

Alendronate Sodium



Clopidogrel Bisulfate



Atomoxetine Hcl



Desmopressin Monoacetate


Divalproex Sodium


Dobutamine Hcl

Bupropion Hcl



Dothiepin Hcl






Escitalopram HBr





Cefuroxime Axetil



Fluticasone Propionate

Citalopram Hbr

Fluvoxamine Maleate

Fosphenytoin Sodium

Copyright Taj Pharmaceuticals Ltd. | Privacy Policy | Terms & Conditions | Sitemap

Investor Relations    Feedback     Contact Worldwide    Sitemap


taj group logo
2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Ltd products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.